Fig. 2From: The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world settingSpaghetti plots of change from baseline in %Bronchiectasis and %Disease over two yearsBack to article page